Level 9, Suite 1, 68 Pitt Street,
Sydney, NSW, 2000, Australia
+61 (02) 8964 7401
Actinogen Medical is a publicly listed (ASX: ACW) clinical-stage biotechnology company undertaking research in Alzheimer’s disease and other chronic neurodegenerative diseases.
Actinogen Medical’s lead research candidate, Xanamem™, is a novel drug under development for the treatment of Alzheimer’s disease. Research recently demonstrated that increased cortisol, also known as the “stress hormone”, is associated with cognitive impairment, the development of beta-amyloid plaques and nerve death in the brain – the hallmarks of Alzheimer’s disease. Xanamem™, has been specifically designed to block the production of cortisol in the brain.
Actinogen has successfully completed all the necessary early phase studies to confirm that Xanamem™ is well tolerated with an acceptable safety profile, and that it crosses the blood-brain-barrier in concentrations to adequately inhibit the excess production of cortisol in the hippocampus and frontal cortex of the brain, its primary site of action.
Actinogen is well advanced in its plans for the Phase II “XanADu” efficacy and safety study with mild Alzheimer’s disease patients in the second half of 2016. This study will be run in Australia, the United Kingdom, and the United States with appropriate regulatory approvals.
Dr Brooke is a clinically trained physician turned venture capitalist with over 30 years’ experience in the healthcare investment industry. He was the founder and managing director of two venture capital firms, Medvest Inc and GBS Venture Partners, which is viewed as one of the Asia Pacific region’s premier healthcare venture investors.
Dr Brooke has been a major investor, chairman or director of companies in the healthcare sector with a combined realised value of $1.5 billion. Dr Brooke’s expertise includes assisting high growth technology-based companies in areas such as development strategy, clinical trial design, fund raising, management structuring and investment exits.
Dr Brooke is a medical graduate of the University of Melbourne and has an MBA from IMEDE (now IMD), Lausanne Switzerland.
Dr. Bill Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional, with 30 years experience in the industry, including senior medical and management roles with global pharmaceutical giant, Pfizer. Prior to joining Actinogen Medical, Dr. Ketelbey was Regional Vice President of Medical Affairs for Pfizer’s Primary Care Business Unit for Australia and New Zealand, Japan, Canada, Korea and Country Medical Director for Pfizer Australia and New Zealand.
Dr. Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer’s disease. At Pfizer, Dr. Ketelbey led the Australian/New Zealand clinical development, and was involved in the launch and commercialisation of Aricept™ (donepezil), an acetylcholinesterase inhibitor, the market leading Alzheimer’s disease therapy locally and globally. More recently, he was involved in developing monoclonal antibodies directed at amyloid plaques, a hallmark of Alzheimer’s.
Dr. Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa, a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom, has an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors.
Dr. Loveridge has been working in the biomedical technology industry for over 20 years and has extensive experience in developing clinical stage biotechnology companies. As a venture investor with JAFCO Nomura, Dr. Loveridge participated and invested in the start-up of over 24 companies in Europe, the United States and Israel. Since 2005, he has been directly involved in the senior management of a number of small innovative companies in the biomedical field, specifically in refinancing and product commercialisation.
Dr. Loveridge is currently a Non-Executive Director of Resonance Health (ASX: RHT).
Dr. Uvarov has significant experience as an equity analyst in the healthcare industry with a focus on biotechnology sector, both domestically and internationally. Prior to moving to Australia he was with Citigroup Global Markets where he spent two years as a member of New York based biotechnology team that has been continuously ranked top 4 for Biotechnology in the All-America Institutional Investor survey. Dr. Uvarov’s scientific expertise and company knowledge spreads across variety of therapeutic areas and spectrum of market capitalizations with his particular interest in early stage biotechnology companies.
Dr. Uvarov holds a PhD degree in Biochemistry and Medical Genetics from the University of Manitoba, Canada and an MBA degree from the University of Calgary, Canada. He is currently a Director of Actinogen Medical (ASX.ACW) – an Australian clinical stage biotechnology company developing therapies for Alzheimer’s and other neurodegenerative diseases, and Imugene Limited (ASX.IMU) – an Australian immuno-oncology company.
Mr. Webse has over 23 years of company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance, and corporate advisory services. Mr. Webse is a non-executive director of Cynata Therapeutics Limited.
The Board will be chaired by Craig Ritchie, Professor of The Psychiatry of Ageing at the University of Edinburgh. Professor Ritchie is a leading authority on clinical trials in dementia and has been senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition.
He has extensive knowledge of the industry, having sat on advisory boards of numerous pharmaceutical companies, biotechnology companies, and clinical research organizations, all with an in interest in developing drugs and trial infrastructure for Alzheimer’s disease.
Professor Ritchie is also leading the PREVENT project, a major Scottish initiative to identify mid-life risks for dementia, as well as the EPAD (European Prevention of Alzheimer’s Dementia) consortium, to better understand early aspects of Alzheimer’s disease before dementia develops. He has published extensively on the topics of dementia and delirium.
Professor Colin Masters AO is currently the Executive Director of the Mental Health Research Institute, and a Laureate Professor at the University of Melbourne. He is also the Senior Deputy Director of the Florey Institute of Neuroscience and Mental Health, and a consultant at the Royal Melbourne Hospital.
He has focused his career on research in Alzheimer’s disease and other neurodegenerative diseases. With over 35 years’ experience, he is widely acknowledged as having had a major worldwide influence on Alzheimer’s disease research and the causes of the disease. More recently, his focus has been on describing the natural history of Alzheimer’s disease as a necessary preparatory step for therapeutic disease modification.
Professor Masters is also a driving force behind the AIBL (Australian Imaging, Biomarkers & Lifestyle) study to determine which biomarkers, cognitive characteristics, and health and lifestyle factors determine subsequent development of Alzheimer’s.
Professor Jeff Cummings is the Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
He is a world-renowned Alzheimer’s researcher and leader of clinical trials and has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Research Award of the John Douglas French Alzheimer’s Research Foundation (2008), and the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008). In 2010, he was honoured by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award.
Professor Cummings has a strong interest in clinical trials, developing new therapies for brain diseases and the interface of neuroscience and society. He is a past president of the Behavioural Neurology Society and of the American Neuropsychiatric Association and has authored or edited 39 books and published over 650 peer-reviewed papers.
A graduate in Biochemistry and Medicine from the University of Birmingham, Professor Boyd is President of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, UK. He is also an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School.
Professor Boyd began his 30 year pharmaceutical career with Glaxo Group Research Ltd. He led ICI’s cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada. After four years as Head of Medical Research for Zeneca Pharmaceuticals (now Astra Zeneca), he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for the development of their gene based medicines portfolio. In 2005, Professor Boyd set up Boyd Consultants, the focus of which is to aid and support early stage life-science based companies.
Professor Walker is a Clinical Professor of Endocrinology and Head of the University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science.
His prolific translational research over 20 years has concerned the role of glucocorticoids in metabolic syndrome and cardiovascular disease. He published the original description of 11β-HSD1 as an amplifier of glucocorticoid action, identifying this enzyme as a prime therapeutic target.
Professor Walker co-chairs the Cortisol Network (CORNET) international consortium that has conducted GWAS meta-analyses for cortisol. He is Co-Director of the Edinburgh Clinical Academic Training (ECAT) scheme, mentor to its many recruits in various disciplines, former chair of the development group of the Edinburgh MSc in Translational Medicine, and has been a member of The Wellcome Trust’s Clinical Interview Committee since 2007. He has extensive experience collaborating with and advising for pharmaceutical R&D.
Dr. Webster is a Senior Lecturer and Director of Drug Discovery Core at the College of Medicine and Veterinary Medicine, University of Edinburgh with a focus on translational research for the treatment of conditions such as Alzheimer’s disease, cardiovascular disease and acute pancreatitis.
His work has led to the discovery of a number of potent small molecule inhibitors of target enzymes, one of which has completed phase 1 clinical trials in humans, two DPAc collaborative drug discovery programmes with GSK focused on acute pancreatitis and liver fibrosis, and a collaboration with a US-based pharmaceuticals company focused on remyelination therapy for treatment of multiple sclerosis.
Dr. Webster is also a drug discovery advisor for the Wellcome Trust. Prior to joining the University Dr. Webster was head of enzymology at PanTherix Ltd, with responsibility for leading several drug discovery programmes.
Mr. Ruffles has 20 years of experience in the pharmaceutical and biotechnology industries, and has worked across all phases of the drug development cycle. Mr. Ruffles began his career in the United Kingdom at Hoechst-Roussel (now Sanofi) and relocated to Geneva, Switzerland to work for Serono (now Merck Serono). After returning to the United Kingdom to work at Procter & Gamble and then Amgen, Mr. Ruffles moved to Sydney, Australia in 2008.
He has worked on several drugs taking them through clinical development and has extensive experience in Alzheimer’s disease and related therapeutic areas. Mr. Ruffles’ recent role in a global contract research organisation has given him great exposure to the Asia Pacific region and a variety of companies and their needs including local start-up pharmaceutical companies with limited resources but significant potential and multinational clients.
Mr. Ruffles will be responsible for providing the overall research and regulatory operational oversight of the research clinical program of Xanamem™.
Kerrie joined Actinogen in September 2015 bringing with her over 20 years of industry experience in clinical operations and project management.
She has held various roles within CRO’s, pharmaceutical companies, SMO’s, start-ups, and also as an independent contractor. She has been responsible for project teams and delivery across many regions including Australia/New Zealand, Taiwan, Korea, Singapore, Hong Kong, and Russia, as well as having spent several years working and managing studies while based in the United States.
Kerrie’s therapeutic experience has mainly focused in oncology, but also includes urology, dermatology, diabetes, haematology, hepatology, neurology, and infectious disease.
Bridget has a Masters in Brain and Mind Sciences (MBMSc) from The University Sydney’s Faculty of Medicine. Her background includes a Bachelor of Science (B. Sc) Degree in Psychology with dual minors in Biology and Cognitive Science from The University of North Carolina at Charlotte, United States. Bridget’s interest in the interdisciplinary investigation of disease areas of the mind and brain inspired her towards a career in advancing medical research for future generations.